~~<i id='B4D5AB3055'><strike id='B4D5AB3055'><tt id='B4D5AB3055'><pre id='B4D5AB3055'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

entertainment

author：hotspot 2025-09-29 22:50:37 - browse：11

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

entertainment

leisure time

explore

focus

Wikipedia

leisure time

AdobeKalVistaPharmaceuticalssaidTuesdaythatitsoral,on-demandtreatmentfortheswelling“attacks”commonly

WSS

Ransomware attacks on hospitals: Study outlines patient impact

Vaccine advisory panel ACIP left half staffed by HHS

The Readout: Gilead, Bernie Sanders, and other pharma news

Biogen Alzheimer’s drug launch off to slow start

'Revelatory' study finds a smoking impact that remains after quitting

Doctors' information doesn't help them choose wisely when sick

hotspot

entertainment

entertainment

Affirmative action in medical school literally saved lives

Anthos stroke drug appears safer than common blood thinner

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Biden report: The neurospychology of memory and aging

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

To avoid data mishandling cases, universities eye AI and other tools

Psychedelics group wrestles with new pharma identity

Doctors' information doesn't help them choose wisely when sick

Heart attack and stroke risk calculators need revising

World's first CRISPR

leisure time

Poor hospice wound care hurts patients and families

U.K. considers world's first use of meningitis vaccine to address gonorrhea

NYU radiologists take on the challenge of expensive MRI machines

NYU radiologists take on the challenge of expensive MRI machines

World's first CRISPR

PBM reforms clear House panel

explore

focus

Wikipedia

leisure time